Explore 3 Stock Ideas & Industry Insights Download Free Report

Alseres Pharmaceuticals Inc

Company price
None USD 0.00(0%)
Last update at 2024-11-17T21:00:22.942542Z
Market Cap
0.20M

Momentum Score

…

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.01
Dividend Yield
4.88%
Revenue TTM
0.47M
Revenue Per Share
-
Gross Profit TTM
0.45M
Debt / Equity
-0.73
ROE
-
Net Debt
7.71M
ROCE
74.91%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Income before tax -0.94M -1.65M -1.04M 3.16M -8.25M
Net income -0.94M -1.65M -2.88M 0.51M -10.78M
Selling general administrative 1.42M 1.67M 2.03M 2.66M 8.25M
Gross profit 0.47M 0.53M 0.00M 0.00M -
Ebit -0.95M -1.19M -2.09M -9.40M -8.40M
Ebitda -0.94M -1.18M -2.04M -9.34M -8.33M
Depreciation and amortization 0.00M 0.00M 0.04M 0.06M 0.07M
Operating income -0.56M -1.21M -1.57M -3.12M -8.33M
Other operating expenses 1.42M 1.72M 1.57M 3.12M 8.33M
Interest expense 0.45M 0.43M 1.84M 2.64M 2.52M
Income tax expense 0.45M 0.43M 1.32M -3.64M 2.45M
Total revenue 0.47M 0.53M 0.00M 0.00M -
Total operating expenses 1.42M 1.72M 1.57M 3.12M 8.33M
Cost of revenue 0.02M 0.03M 0.00M 0.00M -
Total other income expense net 0.46M -0.03M 0.52M 6.28M 0.07M
Net income from continuing ops -0.94M -1.65M -2.88M 0.51M -
Net income applicable to common shares -0.94M -1.65M -2.88M 0.14M -
Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Total assets 0.39M 0.97M 0.17M 0.46M 0.79M
Other current assets 0.01M 0.04M 0.01M 0.10M 0.07M
Total liab 11.05M 27.69M 30.77M 47.75M 48.30M
Total stockholder equity -10.66M -26.72M -30.60M -47.29M -47.51M
Deferred long term liab 0.06M 0.06M - - -
Other current liab 0.52M 3.58M 2.70M 4.71M 0.06M
Common stock 0.31M 0.31M 0.31M 0.27M 0.26M
Retained earnings -199.64M -198.69M -197.05M -194.17M -194.68M
Other liab 1.19M 17.25M - 0.03M 4.15M
Other assets 0.06M 0.06M - 0.20M 0.30M
Cash 0.11M 0.02M 0.14M 0.10M 0.31M
Total current liabilities 1.65M 10.07M 30.42M 42.29M 4.92M
Current deferred revenue 0.07M 0.07M - - -
Net debt 7.71M 6.39M 27.59M 33.66M 35.34M
Short term debt 0.51M 6.41M 27.73M 33.73M 1.40M
Short long term debt 8.32M 6.74M 21.83M 29.00M -
Short long term debt total 7.82M 6.41M 27.73M 33.76M 35.65M
Other stockholder equity 188.66M 171.98M 166.17M 146.61M 146.91M
Property plant equipment - 0.00M 0.00M 0.05M 0.11M
Total current assets 0.32M 0.90M 0.17M 0.21M 0.39M
Net tangible assets -10.66M -26.72M -30.60M -47.29M -
Short term investments 0.21M 0.88M 0.03M 0.10M 0.04M
Long term debt 7.82M - - - 34.16M
Accounts payable 1.06M 3.52M 1.42M 3.85M 3.46M
Accumulated other comprehensive income 0.01M -0.31M -0.03M - -
Preferred stock total equity 0.39M 0.37M 0.35M 5.43M 5.07M
Non currrent assets other - 0.06M - - -
Non current assets total 0.06M 0.07M 0.00M 0.25M 0.40M
Breakdown 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Type yearly yearly yearly yearly yearly
Date 2013-12-31 2012-12-31 2011-12-31 2010-12-31 2009-12-31
Investments 0.88M 0.88M 0.88M - -
Change to liabilities -1.30M 0.27M -0.89M 0.12M 0.33M
Total cashflows from investing activities 0.88M 0.88M 0.30M 0.04M 0.08M
Net borrowings 0.90M 0.83M 2.24M 2.71M -
Total cash from financing activities 0.90M 0.83M 2.22M 2.70M 8.22M
Change to operating activities 0.00M 0.42M 1.74M 1.82M -
Net income -0.94M -1.65M -2.88M 0.51M -10.78M
Change in cash 0.10M -0.12M 0.04M -0.22M 0.24M
Begin period cash flow 0.02M 0.14M 0.10M 0.31M 0.07M
End period cash flow 0.11M 0.02M 0.14M 0.10M 0.31M
Total cash from operating activities -1.69M -0.95M -2.48M -2.95M -8.06M
Depreciation 0.00M 0.00M 0.04M 0.06M 0.07M
Other cashflows from investing activities 0.88M 0.88M 0.30M 0.04M 0.08M
Sale purchase of stock - -0.00M -0.02M -0.01M -
Other cashflows from financing activities 0.90M 0.83M 2.24M 3.31M 6.25M
Change to netincome 0.55M 0.55M -0.50M -5.47M -
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -1.29M 0.69M 0.85M 0.93M 0.45M
Other non cash items 0.55M - -3.38M -4.46M 2.19M
Free cash flow -1.69M -0.95M -2.49M -2.95M -8.06M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Alseres Pharmaceuticals Inc

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

275 Grove Street, Auburndale, MA, United States, 02466

617-419-3289

Name Title Year Born
Mr. Peter G. Savas Exec. Chairman 1948
Mr. Sam Martin Director of Fin. & Corp. Compliance NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…